Efficacy
Women RECONNECT with their sexual desire
The RECONNECT clinical trials for Vyleesi studied the defining symptoms of HSDD1,2
Primary endpoints evaluated1:
desire
Change in Female Sexual Function Index-Desire Domain (FSFI-D) Score to measure improvement in sexual desire from baseline to Week 24
&
distress*
Change in Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 Score to measure reduction in associated distress from baseline to Week 24
Key secondary endpoint evaluated1,3:
Change in number of Satisfying Sexual Events (SSEs) based upon the Revised Female Sexual Encounter Profile (FSEP-R)
HSDD=hypoactive sexual desire disorder.
*Distress is defined as including feelings of frustration, grief, incompetence, loss, sadness, sorrow, or worry.4
CO-PRIMARY ENDPOINT #1
Significant increase in sexual desire
Women taking Vyleesi experienced a significant increase in desire compared to those taking placebo1

FSFI=Female Sexual Function Index; FSFI-D=Female Sexual Function Index-Desire Domain.
†Analysis based on MITT (modified intent to treat) defined as all subjects who were randomized, used at least 1 dose of the double-blind study drug, and had at least 1 double-blind follow-up visit.1
‡P-value from unadjusted Van Elteren test stratified by study.3
Women taking Vyleesi saw improvement in their low sexual desire at the first assessment—improvement continued over time1,3

‖All Assessment Months were statistically significant—Months 1-6 (P<0.05).¶
The score for Vyleesi was 2.06 compared to placebo (2.04) at baseline. Scores range from 1.2 (lowest desire) to 6 (highest desire). The desire domain encompasses the first 2 questions in the FSFI.3
§Analysis based on MITT (modified intent to treat) defined as all subjects who were randomized, used at least 1 dose of the double-blind study drug, and had at least 1 double-blind follow-up visit.1
¶P-value from unadjusted Van Elteren test stratified by study.3
In October 2016, the FDA updated draft guidance for all clinical trials for hypoactive sexual desire disorder. Validated patient-reported outcomes (PROs) are appropriate to be used when evaluating change in sexual desire (FSFI-D) with interventions5
The FSFI is a 19-item, validated questionnaire used to measure overall sexual function in women. Sexual desire is measured using questions 1 and 2 within the Desire Domain (FSFI-D)5
In clinical trials, women are asked to rate desire using the Likert scale
Q1
Over the past 4 weeks, how often did you feel sexual desire or interest?
(Answer 1=almost never or never to 5=almost always or always)
Q2
Over the past 4 weeks, how would you rate your level (degree) of sexual desire or interest?
(Answer 1=very low or none at all to 5=very high)
The 2 response scores are summed, and raw scores are multiplied by a factor of 0.6, providing a sexual desire domain score that ranges from 1.2 to 6.0.
An increase in the FSFI-D domain score denotes improvement in sexual desire5


FDA=Food and Drug Administration.

CO-PRIMARY ENDPOINT #2
Significant decrease in distress
Women taking Vyleesi experienced a significant decrease in distress compared to those taking placebo1

FSDS-DAO=Female Sexual Distress Scale-Desire/Arousal/Orgasm.
#Analysis based on MITT (modified intent to treat) defined as all subjects who were randomized, used at least 1 dose of the double-blind study drug, and had at least 1 double-blind follow-up visit.1
**P-value from unadjusted Van Elteren test stratified by study.4
Women taking Vyleesi saw a reduction in distress at the first assessment—decrease continued over time1,3

‡‡All Assessment Months were statistically significant—Months 1-6 (P<0.05).§§
The score for both treatment groups was 2.9 at baseline. Scores ranged from 0 (Never feel bothered) to 4 (Always feel bothered). Distress related to sexual desire is measured using Question 13 of the FSDS-DAO.3,5
††Analysis based on MITT (modified intent to treat) defined as all subjects who were randomized, used at least 1 dose of the double-blind study drug, and had at least 1 double-blind follow-up visit.1
§§P-value from unadjusted Van Elteren test stratified by study.3
In October 2016, the FDA updated draft guidance for all clinical trials for hypoactive sexual desire disorder. Validated patient-reported outcomes (PROs) are appropriate to be used when evaluating change in personal distress (FSDS-DAO Item 13) with interventions5
The FSDS-DAO is a 15-item, validated questionnaire used to measure different aspects of sexual distress. Item 13 asks women to rate their level of distress related to low sexual desire5,6
In clinical trials, women are asked to rate distress using the Likert scale
Q13
How often did you feel bothered by low sexual desire?
(Answer 0=never to 4=always)
A decrease in the FSDS-DAO Item 13 score denotes improvement in the level of distress associated with low sexual desire5


FDA=Food and Drug Administration.

KEY SECONDARY ENDPOINT
Number of satisfying sexual events (SSEs)
There were no statistically significant differences between treatment groups and placebo in the change in the number of SSEs3
The Food and Drug Administration (FDA) no longer requires the number of SSEs to be a co-primary endpoint in clinical trials because it is not part of the diagnosis of HSDD.5
HSDD=hypoactive sexual desire disorder.
STUDY DESIGN
Over 1,200 women were involved in the pivotal trials
Clinical data included 2 identical, 24-week, randomized, double-blind, placebo-controlled core studies and 2 voluntary, 52-week, open-label extension studies.1,3,7

Baseline characteristics1
- 19-56 years old (premenopausal); average age was 39
- Mean duration of 4 years with acquired, generalized HSDD
- Racial demographics: Caucasian (86%), Black (12%)
- Female, ≥18 years of age, and premenopausal
- Had previously experienced a normal level of desire for a period of at least 2 years
- Willing to engage in sexual activity at least once a month during the study
- In a stable relationship for at least 6 months
- Satisfied the diagnostic criteria for HSDD (per Diagnostic Screening Guide for HSDD) for at least 6 months
- Not pregnant
- On birth control for 3 months before first screening, continuing for the duration of the study and 1 month following end of study (heterosexual couples)
- Postmenopausal
- Pregnant or nursing
- Had a history of psychiatric or mental illness and/or alcohol/substance abuse (within 6 months before screening)
- Used medications: testosterone (within 6 months before screening), neuroleptics, lithium, antidepressants, mood stabilizers, benzodiazepines, stimulants, and certain nutritional supplements (within 3 months before screening).
HSDD=hypoactive sexual desire disorder.

INDICATION
VYLEESI is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to:
- A co-existing medical or psychiatric condition,
- Problems with the relationship, or
- The effects of a medication or drug substance.
Acquired HSDD refers to HSDD that develops in a patient who previously had no problems with sexual desire. Generalized HSDD refers to HSDD that occurs regardless of the type of stimulation, situation or partner.
Limitations of Use
- VYLEESI is not indicated for the treatment of HSDD in postmenopausal women or in men.
- VYLEESI is not indicated to enhance sexual performance.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
VYLEESI is contraindicated in patients who have uncontrolled hypertension or known cardiovascular disease.
WARNINGS AND PRECAUTIONS
Transient Increase in Blood Pressure and Decrease in Heart Rate: VYLEESI transiently increases blood pressure and reduces heart rate after each dose. Advise patients that these changes usually resolve within 12 hours. VYLEESI is not recommended in patients at high risk for cardiovascular disease. Consider the patient’s cardiovascular risk before initiating VYLEESI and periodically during treatment and ensure blood pressure is well-controlled. To minimize the risk of more pronounced blood pressure effects, patients should not take more than one VYLEESI dose within 24 hours. Patients should not use more than 8 VYLEESI doses per month.
Focal Hyperpigmentation: Reported by 1% of patients who received up to 8 doses per month, including involvement of the face, gingiva and breasts. Patients are at higher risk of developing focal hyperpigmentation if they have darker skin and with daily dosing. Resolution of the focal hyperpigmentation was not confirmed in all patients after discontinuation of VYLEESI. Consider discontinuing VYLEESI if hyperpigmentation develops.
Nausea: Reported by 40% of patients who received up to 8 monthly doses, requiring anti-emetic therapy in 13% of patients and leading to premature discontinuation for 8% of patients. Nausea improves for most patients with the second dose. Consider discontinuing VYLEESI or initiating anti-emetic therapy for persistent or severe nausea.
ADVERSE REACTIONS
Most common adverse reactions (incidence >4%) are nausea, flushing, injection site reactions, headache, and vomiting.
DRUG INTERACTIONS
VYLEESI may slow gastric emptying and impact absorption of concomitantly administered oral medications. VYLEESI may significantly decrease the systemic exposure of orally-administered naltrexone; avoid use with orally administered naltrexone-containing products intended to treat alcohol or opioid addiction.
PREGNANCY
Advise patients to discontinue VYLEESI if pregnancy is suspected. Advise patients to use effective contraception while taking VYLEESI.
A pregnancy exposure registry monitors pregnancy outcomes in women exposed to VYLEESI during pregnancy. Pregnant women exposed to VYLEESI and healthcare providers are encouraged to call the VYLEESI Pregnancy Exposure Registry at 1-800-922-1038.
Please see full Prescribing Information.
References: 1. VYLEESI [package insert]. Bridgewater, NJ: Cosette Pharmaceuticals, Inc.; 2024. 2. Koochaki P, Revicki D, Wilson H, et al. Conversations with participants in the RECONNECT studies about their experiences with bremelanotide for treatment of hypoactive sexual desire disorder. Presented at: International Society for the Study of Women’s Sexual Health (ISSWSH)/International Society for Sexual Medicine (ISSM) Joint Meeting; March 7-10, 2019; Atlanta, GA. 3. Data on File, Cosette Pharmaceuticals, Inc.; Integrated summary of efficacy: bremelanotide. 4. Parish SJ, Goldstein AT, Goldstein SW, et al. Toward a more evidence-based nosology and nomenclature for female sexual dysfunctions—part II. J Sex Med. 2016;13(12):1888-1906. 5. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. Low sexual interest, desire, and/or arousal in women: developing drugs for treatment. Fed Reg. 2016;1(1):1-12. 6. Dickstein JB, Goldstein SW, Tkachenko N, Kreppner W. Correlation of question 15 of the FSDS-DAO with clinician evaluation of female orgasmic disorder. J Sex Med. 2013;10(9):2251-2254. 7. Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019 Nov;134(5):899-908.
